Paclitaxel in Combination With Bevacizumab in Patients With Stage IV NSCLC. (AVATAX)
Retrospective Multicenter Study of Paclitaxel in Combination With Bevacizumab in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC).
研究概览
地位
条件
详细说明
Lung and bronchopulmonary cancer is the leading cause of cancer death in France and worldwide. It is diagnosed at the metastatic stage from the outset in approximately 50% of cases. Non-small cell lung cancers (NSCLC) are the most frequent histological forms of lung cancer (approximately 85% of cases) with a predominance of the non-epidermal type.
The increase in the number of treatments available, improved supportive care and better patient selection have, in recent years, made it possible to expand the range of first-line chemotherapy treatments available at delà̀ and have contributed to the increase in overall survival (OS). As a result, nearly 80% of patients with metastatic NSCLC receive a second line of treatment. The main objective in these often symptomatic patients is a satisfactory tumor control rate with acceptable tolerability.
For a long time, the second-line reference chemotherapy has been docetaxel or pemetrexed as monotherapy with modest results. Alternative treatments such as the combination of paclitaxel (chemotherapy)-bevacizumab (anti-angiogenic monoclonal antibody) have been studied. Since 2010, by analogy with breast cancer and in the absence of therapeutic alternatives, the paclitaxel-bevacizumab doublet has been used in non-epidermal stage IV NSCLC in France. The value of combining taxane chemotherapy with an anti-angiogenic molecule has been demonstrated in two Phase 3 clinical trials. Thus, this combination is an integral part of the possible treatments in 2nd line and beyond, registered since 2016 in the treatment guidelines for non-epidermal NSCLC.
The first-line therapeutic strategy will also be redefined in 2019 with the use of immunotherapy for a majority of patients. Subsequent treatment lines will be modified, with a focus on chemotherapy, in particular the paclitaxel-bevacizumab combination.
As this combination has been used in current practice for several years, and in view of the upcoming changes to the first and second line of NSCLC treatment, data on the efficacy and tolerance of this combination in real life are needed to guide our practices. Recent studies are also looking at the efficacy of chemotherapy, particularly taxane chemotherapy associated with an anti-angiogenic agent after a previous line including immunotherapy, with a favorable signal.
The aim of the study is to evaluate the paclitaxel-bevacizumab combination retrospectively and multicenter in current practice, with subgroup analyses of the following patients: patients who have previously received immunotherapy, patients with an EGFR or ALK oncogenic addiction pathway, patients who have previously received taxanes or anti-angiogenic agents.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Boulogne Billancourt、法国
- Hôpital Ambroise Paré AP-HP
-
Brest、法国
- Centre Hospitalier Universitaire Brest
-
Chambéry、法国
- Centre Hospitalier Metropole Savoie
-
Créteil、法国
- Centre Hospitalier Intercommunal De Créteil
-
Grenoble、法国
- Centre Hospitalier Universitaire Grenoble Alpes
-
Le Chesnay、法国
- Centre Hospitalier de Versailles André Mignot
-
Lille、法国
- Centre Hospitalier Universitaire de Lille
-
Lyon、法国
- Hospices Civils de Lyon
-
Lyon、法国
- Centre Léon Bérard Lyon
-
Mantes-la-Jolie、法国
- Centre Hospitalier François Quesnay
-
Metz-Tessy、法国、74374
- Centre Hospitalier Annecy Genevois
-
Paris、法国
- Institut Curie
-
Saint-Cloud、法国
- Institut Curie Saint Cloud
-
Saint-Étienne、法国
- Institut de Cancérologie Lucien Neuwirth
-
Suresnes、法国
- Hopital Foch
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- At least 18 years old;
- Histologically or cytologically confirmed diagnosis of non-epidermal NSCLC;
- Advanced stage IV disease at the start of treatment with paclitaxel-bevacizumab according to TNM 7/8th edition classification;
- Treatment with paclitaxel-bevacizumab received as second-line therapy or beyond, in a clinical trial or not;
- Alive patients not opposed to the use of their data
Exclusion Criteria:
- Patient under guardianship or curatorship at the date of the study ;
- Patients alive at the time of the study who are opposed to the use of their data
- Opposition to the use of their data expressed during the lifetime of patients who died at the time of the study.
学习计划
研究是如何设计的?
设计细节
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Progression-free survival
大体时间:Up to 12 months
|
Progression-free survival with paclitaxel-bevacizumab, i.e., the time from the start of paclitaxel-bevacizumab treatment to cancer progression, estimated at 12 months in the general population.
|
Up to 12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
---|---|---|
Drugs administration dosage description
大体时间:Up to 12 months
|
Description of the different monthly drug administration regimens
|
Up to 12 months
|
Objective response rate and control rate
大体时间:Up to 12 months
|
Objective response rate and control rate according to RECIST 1.1 criteria in the general population
|
Up to 12 months
|
Overall survival Rate
大体时间:Up to 12 months
|
Overall survival, assessed on the whole population
|
Up to 12 months
|
Objective Response Rate
大体时间:Up to 12 months
|
Objective Response Rate in the following subgroups:
|
Up to 12 months
|
Progression-Free Survival Rate
大体时间:Up to 12 months
|
Progression-Free Survival in the following subgroups:
|
Up to 12 months
|
Disease Control Rate
大体时间:Up to 12 months
|
Disease Control in the following subgroups:
|
Up to 12 months
|
Overall Survival Rate
大体时间:Up to 12 months
|
Overall Survival in the following subgroups:
|
Up to 12 months
|
Frequency of safety events
大体时间:Up to 12 months
|
Frequency of grade ≥3 adverse events and frequency of discontinuation of paclitaxel-bevacizumab for toxicity ;
|
Up to 12 months
|
合作者和调查者
调查人员
- 首席研究员:Chantal Decroisette、Ch Annecy Genevois
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.